Shanna Arnold
Last active: 4/18/2017

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Larger core size has superior technical and analytical accuracy in bladder tissue microarray. Eskaros AR, Egloff SA, Boyd KL, Richardson JE, Hyndman ME, Zijlstra A (2017) Lab Invest 97(3): 335-342
    › Primary publication · 28112755 (PubMed)
  2. Core Needle Biopsy and Fine Needle Aspiration Alone or in Combination: Diagnostic Accuracy and Impact on Management of Renal Masses. Cate F, Kapp ME, Arnold SA, Gellert LL, Hameed O, Clark PE, Wile G, Coogan A, Giannico GA (2017) J Urol 197(6): 1396-1402
    › Primary publication · 28093293 (PubMed)
  3. New and Emerging Diagnostic and Prognostic Immunohistochemical Biomarkers in Prostate Pathology. Giannico GA, Arnold SA, Gellert LL, Hameed O (2017) Adv Anat Pathol 24(1): 35-44
    › Primary publication · 27941540 (PubMed)
  4. Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. Arnold Egloff SA, Du L, Loomans HA, Starchenko A, Su PF, Ketova T, Knoll PB, Wang J, Haddad AQ, Fadare O, Cates JM, Lotan Y, Shyr Y, Clark PE, Zijlstra A (2017) Oncotarget 8(1): 722-741
    › Primary publication · 27894096 (PubMed) · PMC5352192 (PubMed Central)
  5. MAGI-2 in prostate cancer: an immunohistochemical study. Goldstein J, Borowsky AD, Goyal R, Roland JT, Arnold SA, Gellert LL, Clark PE, Hameed O, Giannico GA (2016) Hum Pathol : 83-91
    › Primary publication · 26980016 (PubMed)
  6. Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome. Hansen AG, Freeman TJ, Arnold SA, Starchenko A, Jones-Paris CR, Gilger MA, Washington MK, Fan KH, Shyr Y, Beauchamp RD, Zijlstra A (2013) Cancer Res 73(10): 2955-64
    › Primary publication · 23539446 (PubMed) · PMC3660148 (PubMed Central)
  7. Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation. Arnold SA, Rivera LB, Carbon JG, Toombs JE, Chang CL, Bradshaw AD, Brekken RA (2012) PLoS One 7(2): e31384
    › Primary publication · 22348081 (PubMed) · PMC3279359 (PubMed Central)
  8. Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Arnold SA, Rivera LB, Miller AF, Carbon JG, Dineen SP, Xie Y, Castrillon DH, Sage EH, Puolakkainen P, Bradshaw AD, Brekken RA (2010) Dis Model Mech 3(1-2): 57-72
    › Primary publication · 20007485 (PubMed) · PMC2806901 (PubMed Central)
  9. SPARC: a matricellular regulator of tumorigenesis. Arnold SA, Brekken RA (2009) J Cell Commun Signal 3(3-4): 255-73
    › Primary publication · 19809893 (PubMed) · PMC2778590 (PubMed Central)